Literature DB >> 24188630

Classifications of n2 non-small-cell lung cancer based on the number and rate of metastatic mediastinal lymph nodes.

Masaoki Ito1, Yoshinori Yamashita, Yasuhiro Tsutani, Keizo Misumi, Hiroaki Harada, Yoshihiro Miyata, Morihito Okada.   

Abstract

BACKGROUND: Subdivisions of N2 non-small-cell lung cancer (NSCLC) cases based on metastatic status of mediastinal and non-mediastinal lymph nodes have been proposed. This study aimed to evaluate N2 disease classification by mediastinal lymph nodes alone. PATIENTS AND METHODS: We reviewed 187 patients with NSCLC pN1-N2 who were surgically treated to evaluate the proposed classifications: number, rate, nodal zone of metastatic lymph nodes. We evaluated N2 disease classification based on mediastinal lymph nodes alone in 136 pN2 cases.
RESULTS: The number (1-2, 3-5, and 6 ≤) or rate (15%≥, 15%< to 40%>, and 40%≤) classification based on all metastatic lymph nodes was validated by the log-rank test and Cox proportional hazards model. After reclassification by number or rate of metastatic mediastinal lymph nodes alone, a significant difference was maintained among all groups except between the 3-5 and 6 ≤ groups. The 5-year survival rates of the 1-2, 3-5, and 6 ≤ groups were 63.4%, 32.4%, and 18.2%, respectively (1-2 vs. 3-5, P = .015; 3-5 vs. 6 ≤, P = .134). With rate classification, the 5-year survival rates of the 15%≥, 15%-40% (15%< to 40%>), and 40%≤ groups were 56.0%, 27.3%, and 5.04%, respectively (15%≥ vs. 15%-40%, P = .011; 15-40% vs. 40%≤, P = .011). The Spearman's rank correlation coefficient showed a highly significant correlation of metastatic status between mediastinal lymph nodes and all lymph nodes (both P < .001).
CONCLUSION: Classification by number and rate of mediastinal lymph nodes alone enabled subdivision of N2 NSCLC cases. Metastatic status of mediastinal lymph nodes reflects that of all lymph nodes and is prognostic indicators.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymph node; N2 disease; Non–small-cell lung cancer; Prognosis; Tumor staging

Mesh:

Year:  2013        PMID: 24188630     DOI: 10.1016/j.cllc.2013.04.012

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  5 in total

1.  The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer.

Authors:  Qinchen Cao; Baozhong Zhang; Lujun Zhao; Changli Wang; Liqun Gong; Jun Wang; Qingsong Pang; Kai Li; Weishuai Liu; Xue Li; Peng Wang; Ping Wang
Journal:  Tumour Biol       Date:  2015-01-27

Review 2.  Staging lymph node metastases from lung cancer in the mediastinum.

Authors:  Mario D Terán; Malcolm V Brock
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

3.  Risk factors for recurrence after complete resection of pathological stage N2 non-small cell lung cancer.

Authors:  Guangliang Qiang; Chaoyang Liang; Qiduo Yu; Fei Xiao; Zhiyi Song; Yanchu Tian; Bin Shi; Deruo Liu; Yongqing Guo
Journal:  Thorac Cancer       Date:  2015-03-02       Impact factor: 3.500

4.  Prognosis and distribution of lymph nodes metastases in resectable primary pulmonary lymphoepithelioma-like carcinoma: A large cohort from a single center.

Authors:  Xiangyang Yu; Yingsheng Wen; Rongqing Qin; Yongbin Lin; Xuewen Zhang; Weidong Wang; Yongqiang Chen; Lanjun Zhang
Journal:  Thorac Cancer       Date:  2018-01-12       Impact factor: 3.500

5.  The lymph node ratio predicts cancer-specific survival of node-positive non-small cell lung cancer patients: a population-based SEER analysis.

Authors:  Liu Kai; Chen Zhoumiao; Xu Shaohua; Chen Zhao; Li Zhijun; He Zhengfu; Cai Xiujun
Journal:  J Cardiothorac Surg       Date:  2021-01-19       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.